Cognitive and Neuropsychiatric Manifestations of COVID-19 and Effects on Elderly Individuals With Dementia

The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread worldwide and has had unprecedented effects in healthcare systems, economies and society. COVID-19 clinical presentation primarily affects the respiratory system causing bilateral pneumonia, but it is increasingly being recognized as a systemic disease, with neurologic manifestations reported in patients with mild symptoms but, most frequently, in those in a severe condition. Elderly individuals are at high risk of developing severe forms of COVID-19 due to factors associated with aging and a higher prevalence of medical comorbidities and, therefore, they are more vulnerable to possible lasting neuropsychiatric and cognitive impairments. Several reports have described insomnia, depressed mood, anxiety, post-traumatic stress disorder and cognitive impairment in a proportion of patients after discharge from the hospital. The potential mechanisms underlying these symptoms are not fully understood but are probably multifactorial, involving direct neurotrophic effect of SARS-CoV-2, consequences of long intensive care unit stays, the use of mechanical ventilation and sedative drugs, brain hypoxia, systemic inflammation, secondary effects of medications used to treat COVID-19 and dysfunction of peripheral organs. Chronic diseases such as dementia are a particular concern not only because they are associated with higher rates of hospitalization and mortality but also because COVID-19 further exacerbates the vulnerability of those with cognitive impairment. In patients with dementia, COVID-19 frequently has an atypical presentation with mental status changes complicating the early identification of cases. COVID-19 has had a dramatical impact in long-term care facilities, where rates of infection and mortality have been very high. Community measures implemented to slow the spread of the virus have forced to social distancing and cancelation of cognitive stimulation programs, which may have contributed to generate loneliness, behavioral symptoms and worsening of cognition in patients with dementia. COVID-19 has impacted the functioning of Memory Clinics, research programs and clinical trials in the Alzheimer’s field, triggering the implementation of telemedicine. COVID-19 survivors should be periodically evaluated with comprehensive cognitive and neuropsychiatric assessments, and specific mental health and cognitive rehabilitation programs should be provided for those suffering long-term cognitive and psychiatric sequelae.

[1]  S. Lee COVID-19 Pandemic and Mental Health , 2021 .

[2]  A. Egbert,et al.  Brain abnormalities in COVID-19 acute/subacute phase: A rapid systematic review , 2020, Brain, Behavior, and Immunity.

[3]  R. Bilder,et al.  InterOrganizational practice committee recommendations/guidance for teleneuropsychology (TeleNP) in response to the COVID-19 pandemic , 2020, The Clinical neuropsychologist.

[4]  P. Gil,et al.  Clinical presentation and outcome across age categories among patients with COVID-19 admitted to a Spanish Emergency Department , 2020, European Geriatric Medicine.

[5]  Yawen An,et al.  Psychological Distress and Its Correlates Among COVID-19 Survivors During Early Convalescence Across Age Groups , 2020, The American Journal of Geriatric Psychiatry.

[6]  K. Bhaskaran,et al.  Factors associated with COVID-19-related death using OpenSAFELY , 2020, Nature.

[7]  Ju-Hyun Kim,et al.  Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study , 2020, Neurological Sciences.

[8]  Maria Thom,et al.  The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings , 2020, Brain : a journal of neurology.

[9]  K. Bhaskaran,et al.  OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.

[10]  G. Logroscino,et al.  Telemedicine for Delivery of Care in Frontotemporal Lobar Degeneration During COVID-19 Pandemic: Results from Southern Italy. , 2020, Journal of Alzheimer's disease : JAD.

[11]  Xingfen Yang,et al.  A comparison of mortality-related risk factors of COVID-19, SARS, and MERS: A systematic review and meta-analysis , 2020, Journal of Infection.

[12]  H. Miyashita,et al.  Impact of dementia on clinical outcomes in elderly patients with coronavirus 2019 (COVID‐19): an experience in New York , 2020, Geriatrics & gerontology international.

[13]  P. Matthews,et al.  Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study , 2020, The Lancet Psychiatry.

[14]  Lynn Rochester,et al.  Research with older people in a world with COVID-19: identification of current and future priorities, challenges and opportunities , 2020, Age and ageing.

[15]  D. Rentero,et al.  Psychotic symptoms in COVID-19 patients. A retrospective descriptive study , 2020, Psychiatry Research.

[16]  D. Melzer,et al.  ApoE e4e4 Genotype and Mortality With COVID-19 in UK Biobank , 2020, medRxiv.

[17]  D. Kapogiannis,et al.  The Effects of Confinement on Neuropsychiatric Symptoms in Alzheimer's Disease During the COVID-19 Crisis. , 2020, Journal of Alzheimer's disease : JAD.

[18]  Vasuki H. Dandu,et al.  Spectrum of neuropsychiatric manifestations in COVID-19 , 2020, Brain, Behavior, and Immunity.

[19]  I. Deary,et al.  Psychosocial factors and hospitalisations for COVID-19: Prospective cohort study based on a community sample , 2020, Brain, Behavior, and Immunity.

[20]  V. Mor,et al.  An Illustration of SARS‐CoV‐2 Dissemination Within a Skilled Nursing Facility Using Heat Maps , 2020, Journal of the American Geriatrics Society.

[21]  E. Roze,et al.  Mixed central and peripheral nervous system disorders in severe SARS-CoV-2 infection , 2020, Journal of Neurology.

[22]  Pardis C Sabeti,et al.  Neuropathological Features of Covid-19 , 2020, The New England journal of medicine.

[23]  A. Mauleon,et al.  Dementia Care in Times of COVID-19: Experience at Fundació ACE in Barcelona, Spain , 2020, Journal of Alzheimer's disease : JAD.

[24]  E. Mori,et al.  The behavioral pattern of patients with frontotemporal dementia during the COVID-19 pandemic , 2020, International Psychogeriatrics.

[25]  C. Lucetti,et al.  A complication of coronavirus disease 2019: delirium , 2020, Acta Neurologica Belgica.

[26]  M. Cesari,et al.  Facing Dementia During the COVID‐19 Outbreak , 2020, Journal of the American Geriatrics Society.

[27]  F. Humphries,et al.  Functional and cognitive outcomes after COVID-19 delirium , 2020, European Geriatric Medicine.

[28]  P. Ricci,et al.  The silent deaths of the elderly in long-term care facilities during the Covid-19 pandemic: The role of forensic pathology , 2020, The Medico-legal journal.

[29]  M. Heneka,et al.  Immediate and long-term consequences of COVID-19 infections for the development of neurological disease , 2020, Alzheimer's Research & Therapy.

[30]  R. Garg,et al.  Neurological manifestations and COVID-19: Experiences from a tertiary care center at the Frontline , 2020, Journal of the Neurological Sciences.

[31]  M. Benros,et al.  COVID-19 pandemic and mental health consequences: Systematic review of the current evidence , 2020, Brain, Behavior, and Immunity.

[32]  N. Manjunatha,et al.  Neuropsychiatric aspects of COVID-19 pandemic: A selective review , 2020, Asian Journal of Psychiatry.

[33]  R. Pinzon,et al.  Neurologic Characteristics in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis , 2020, Frontiers in Neurology.

[34]  S. Farhadian,et al.  Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. , 2020, JAMA neurology.

[35]  H. Geerts,et al.  Salvaging CNS Clinical Trials Halted Due to COVID‐19 , 2020, CPT: Pharmacometrics & Systems Pharmacology.

[36]  T. Segura,et al.  Neurologic manifestations in hospitalized patients with COVID-19 , 2020, Neurology.

[37]  Hanqing Liu,et al.  Correlation between immune response and self-reported depression during convalescence from COVID-19 , 2020, Brain, Behavior, and Immunity.

[38]  I. Benítez,et al.  Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer’s disease during the COVID‐19 lockdown , 2020, European journal of neurology.

[39]  C. Lucchinetti,et al.  Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology , 2020, Acta Neuropathologica.

[40]  Ebru Temiz,et al.  Severe acute respiratory syndrome coronavirus 2 is penetrating to dementia research. , 2020, Current neurovascular research.

[41]  C. Tsai,et al.  The Neurologic Manifestations of Coronavirus Disease 2019 Pandemic: A Systemic Review , 2020, Frontiers in Neurology.

[42]  S. Arnold,et al.  Clinical Trials and Tribulations in the COVID-19 Era , 2020, The American Journal of Geriatric Psychiatry.

[43]  Paolo Fusar-Poli,et al.  Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic , 2020, The Lancet Psychiatry.

[44]  W. McDonald,et al.  Altered Mental Status as a Novel Initial Clinical Presentation for COVID-19 Infection in the Elderly , 2020, The American Journal of Geriatric Psychiatry.

[45]  M. Trabucchi,et al.  Clinical Presentation of COVID19 in Dementia Patients , 2020, The journal of nutrition, health & aging.

[46]  Victor G. Puelles,et al.  Multiorgan and Renal Tropism of SARS-CoV-2 , 2020, The New England journal of medicine.

[47]  N. Mercuri,et al.  Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection , 2020, Brain, Behavior, and Immunity.

[48]  Emre Kara,et al.  The another side of COVID‐19 in Alzheimer’s disease patients: Drug‐drug interactions , 2020, International journal of clinical practice.

[49]  N. Trotta,et al.  Early postmortem brain MRI findings in COVID-19 non-survivors , 2020, Neurology.

[50]  M. T. Medina,et al.  The neurology of COVID-19 revisited: A proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries , 2020, Journal of the Neurological Sciences.

[51]  J. Higgins,et al.  COVID-19 in Older People: A Rapid Clinical Review , 2020, Age and ageing.

[52]  Grégory Dal Bo,et al.  How to detect and track chronic neurologic sequelae of COVID-19? Use of auditory brainstem responses and neuroimaging for long-term patient follow-up , 2020, Brain, Behavior, & Immunity - Health.

[53]  Antonio Cuesta-Vargas,et al.  Telehealth Home Support During COVID-19 Confinement for Community-Dwelling Older Adults With Mild Cognitive Impairment or Mild Dementia: Survey Study , 2020, Journal of medical Internet research.

[54]  Bernard Harmegnies,et al.  Clinical and epidemiological characteristics of 1420 European patients with mild‐to‐moderate coronavirus disease 2019 , 2020, Journal of internal medicine.

[55]  G. Gao,et al.  Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[56]  J. Sejvar,et al.  Neurological associations of COVID-19 , 2020, The Lancet Neurology.

[57]  Ashlyn M Jendro,et al.  Facetime to reduce behavioral problems in a nursing home resident with Alzheimer's dementia during COVID-19 , 2020, Psychiatry Research.

[58]  M. Bo,et al.  Atypical Presentation of Covid-19 in an Older Adult With Severe Alzheimer Disease , 2020, The American Journal of Geriatric Psychiatry.

[59]  B. Pollock,et al.  Anticipating and Mitigating the Impact of the COVID-19 Pandemic on Alzheimer's Disease and Related Dementias , 2020, The American Journal of Geriatric Psychiatry.

[60]  M. Fiorino,et al.  Access to Care for Dementia Patients Suffering From COVID-19 , 2020, The American Journal of Geriatric Psychiatry.

[61]  S. Kremer,et al.  Neurologic Features in Severe SARS-CoV-2 Infection , 2020, The New England journal of medicine.

[62]  T. Jiang,et al.  The differential psychological distress of populations affected by the COVID-19 pandemic , 2020, Brain, Behavior, and Immunity.

[63]  J. Kohn,et al.  Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms , 2020, Brain, Behavior, and Immunity.

[64]  S. Merler,et al.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.

[65]  Ana Marusic,et al.  Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis , 2020, Journal of clinical medicine.

[66]  T. Rea,et al.  Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington , 2020, The New England journal of medicine.

[67]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[68]  Sharukh Lokhandwala,et al.  Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. , 2020, JAMA.

[69]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[70]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[71]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[72]  E. Ely,et al.  Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms , 2019, Critical Care.

[73]  D. Knopman,et al.  Systemic inflammation during midlife and cognitive change over 20 years , 2019, Neurology.

[74]  Mayur B. Patel,et al.  Co-Occurrence of Post-Intensive Care Syndrome Problems Among 406 Survivors of Critical Illness* , 2018, Critical care medicine.

[75]  D. Gibson,et al.  Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines , 2018, Front. Immunol..

[76]  S. Yoo,et al.  Psychiatric Findings in Suspected and Confirmed Middle East Respiratory Syndrome Patients Quarantined in Hospital: A Retrospective Chart Analysis , 2018, Psychiatry investigation.

[77]  K. Schughart,et al.  Long-Term Neuroinflammation Induced by Influenza A Virus Infection and the Impact on Hippocampal Neuron Morphology and Function , 2018, The Journal of Neuroscience.

[78]  Martin Knapp,et al.  Social isolation, loneliness and health in old age: a scoping review , 2017, Health & social care in the community.

[79]  P. Kehoe,et al.  Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology , 2016, Alzheimer's Research & Therapy.

[80]  T. Rice,et al.  Recovery and outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family caregivers , 2016, Intensive Care Medicine.

[81]  Timothy B. Smith,et al.  Loneliness and Social Isolation as Risk Factors for Mortality , 2015, Perspectives on psychological science : a journal of the Association for Psychological Science.

[82]  Robert A Schoevers,et al.  Feelings of loneliness, but not social isolation, predict dementia onset: results from the Amsterdam Study of the Elderly (AMSTEL) , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[83]  Thomas E Lane,et al.  Inflammation induced by infection potentiates tau pathological features in transgenic mice. , 2011, The American journal of pathology.

[84]  D. Needham,et al.  Long-term complications of critical care , 2011, Critical care medicine.

[85]  A. Kong,et al.  Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. , 2009, Archives of internal medicine.

[86]  M. Tansey,et al.  Molecular Neurodegeneration BioMed Central Review , 2009 .

[87]  E. Lazartigues,et al.  Angiotensin‐converting enzyme 2 in the brain: properties and future directions , 2008, Journal of neurochemistry.

[88]  David K. Meyerholz,et al.  Severe Acute Respiratory Syndrome Coronavirus Infection Causes Neuronal Death in the Absence of Encephalitis in Mice Transgenic for Human ACE2 , 2008, Journal of Virology.

[89]  G. Almazan,et al.  Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice , 2006, Virology.

[90]  R. Hopkins,et al.  Brain atrophy and cognitive impairment in survivors of acute respiratory distress syndrome , 2006, Brain injury.

[91]  J. Koenigsknecht-Talboo,et al.  Microglial Phagocytosis Induced by Fibrillar β-Amyloid and IgGs Are Differentially Regulated by Proinflammatory Cytokines , 2005, The Journal of Neuroscience.

[92]  Karen J. Chan,et al.  Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome. , 2005, American journal of respiratory and critical care medicine.

[93]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[94]  E. Bigler,et al.  Neuropsychological sequelae and impaired health status in survivors of severe acute respiratory distress syndrome. , 1999, American journal of respiratory and critical care medicine.

[95]  G. Wilcock,et al.  Herpes simplex virus type 1 in brain and risk of Alzheimer's disease , 1997, The Lancet.

[96]  A. Silverstein,et al.  Neurologic Manifestations in , 1970 .

[97]  H. Johnson,et al.  A comparison of 'traditional' and multimedia information systems development practices , 2003, Inf. Softw. Technol..

[98]  J. Luban SARS-CoV-2 , 2020 .

[99]  N. Fabrizio,et al.  Age, gender, and territory of COVID-19 infections and fatalities , 2020 .

[100]  K. Demirkan,et al.  COVID-19 Drug Interactions , 2020 .

[101]  R. Dantzer Neuroimmune Interactions: From the Brain to the Immune System and Vice Versa. , 2018, Physiological reviews.

[102]  A. Ruiz,et al.  Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer’s Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study , 2018, The Journal of Prevention of Alzheimer's Disease.

[103]  T. Dunning,et al.  Long-Term Complications , 2008 .